Brain Neoplasms ; pathology ; physiopathology ; DNA Repair ; genetics ; Glioma ; pathology ; physiopathology ; Humans ; Statistics as Topic ; Targeted Gene Repair

Based on Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment (7^th edition), the metabolism and pharmacokinetics of drugs used in clinical treatment of COVID-19 were reviewed. The antiviral drugs include remdesivir, chloroquine/hydroxychloroquine, lopinavir/ritonavir, favipiravir, arbidol, baicalin, baicalein and forsythin. Among them, the metabolism and pharmacokinetics of arbidol, baicalin and forsythin are the research results of the author's laboratory. This article aims to provide reference for the efficacy evaluation and rational drug use of COVID-19.

Objective To investigate the clinical and pathological features of Miyoshi myopathy(MM) with dysferlin protein deficient. Methods The clinical and pathological data of the 3 patients with MM were analysed. Results 3 patients were onset at youngster.The clinical manifestation were myastheria and myoatrophy in distal of lower limbs.1 case combined myalgia and tumefaction in lower limbs at early stage of onset;1 case showed myathenia in proximal of lower limbs.The level of serum creatine phosphokinase (CK) was significantly ligher in the 3 cases (7543 IU/L, 5657 IU/L, 8721 IU/L respectively). The level of serum lactic dehydrogenase (LDH) was significantly higher in the 2 cases (456 IU/L ,636 IU/L respectively).The result of muscle pathology was showed myogenic damage in all the cases. The expression of dysferlin protain in membrane of muscle cells was completely deficient, although the expression of dystrophin was normal. Inflammatory cells infiltration was found in 1 case's muscle tissue. Conclusions The clinical characters of MM patient are onset at youngster,myasthenia and myoatrophy in lower limbs.The deficit of dysferlin protain can be found by pathology.

To define the definite diagnosis of dementia with Lewy bodies(DLB). Three cases of DLB diagnosed by bedside examination,cerebral image or pathology were analysed. These patients had been diagnosed as Alzheimer disease(AD) or AD with Parkinson disease (PD). DLB consisted of the following features as compared with AD:①Slow progressive congnitive decline, especially fluctuating congnitive defect was prominent;② Recurrent visual hallucinations that were typically well formed and detailed;③The extrapyramidal symptoms usually included mild rigidity and bradykinesia, and they almost appeared simultaneously in the extremities; ④Cerebral atrophy was relatively mild. The clinical diagnosis of DLB might be possible on the detailed basis of their peculiar features, but other neurodegeration disorders should be ruled out.

Objective To investigate the effect of neonatal mechanical ventilation on lung function and recurrent respiratory diseases of patients.Methods Lung function and recurrent respiratory diseases were studied in 16 children who had been ventilated at birth and were followed up in 8 years later.Results Fifty percentage of them had recurrent respiratory diseases and 75 % of had lung function abnormalities, in which residual volume/ total lung capacity (RV/ TLC) was 56.25 %,43.7 % (Vmax 25),specific airway resistance (sRaw) and specific airway conductance (sGaw) 50 % respectively. The forced expiratory flow during 25 %-75 % of forced vital capacity (FEF 25 %-75 %) and maximal expiratory flow rate at 50 % FVC (Vmax50) in the high peak respiratory pressure (PIP) group were lower than those in low PIP group (P

Neurotransmitter release during synaptic transmission is mediated by presynaptic active zone. Multiple protein components at the active zone region interact and coordinate with each other to control and regulate docking, priming and fusion of the synaptic vesicles with presynaptic membrane, and to further maintain the normal transmitter release process. This review will discuss the structure, the formation, and the functional regulation of active zones.

Acute Disease ; Hematopoietic Stem Cell Transplantation ; Humans ; Leukemia ; prevention & control ; therapy ; Postoperative Period ; Secondary Prevention

Animals ; Drugs, Chinese Herbal ; pharmacology ; therapeutic use ; Endotoxemia ; blood ; drug therapy ; immunology ; Humans ; Lipopolysaccharide Receptors ; blood ; Lipopolysaccharides ; blood ; Phytotherapy ; Shock, Septic ; blood ; drug therapy ; immunology

0.05).Cmax of domestic and imported rebamipide tablet were (0.56?0.24) and (0.59?0.29)mg?L-1, with that tmax were (1.75?0.92) and (1.98?1.05)h,t1/2(?) were (1.86?1.38) and (1.93?1.45)h,AUC0～∞ were (2.48?1.06) and (2.62?1.35)mg?h?L-1. Conclusion The pharmacokinetics of the two products are similar.

Objective To investigate the mechanisms of inhibitory effect of Erlotinib,an epidermal growth factor(VEGF) receptor inhibitor,on angiogenesis of pancreatic carncer.Methods①In a tube formation assay,Erlotinib(100?mol/L) was applied to the culture media and compared to the serum free media.The expression of vascular endothelial growth factor(VEGF) in BxPC-3 cells treated with Erlo- tinib at different concentrations(5,50,100,200?mol/L) was determined by RT-PCR.②The xeno grafts derived from BxPC 3 cancer cells were inoculated into the BALB/C nude mice.The mice were treated with either Erlotinib(100 mg/kg of Erlotinib oral lavage daily) or saline for four weeks.The vol- ume of the xenografts was measured and the tumor growth rate was calculated.The microvessel density (MVD) of tumor tissue was determined by immunohistochemistry with an antibody against factorⅧ. Results There were less endothelium cells and close hollow tubular structures in grlotinib treated group compared to the control group in the tube formation assay.The mean weight of xenografts in Erlotinib treated group[(0.397?0.550)g] was significantly lower than that in the control group[(1.570?1.060)g] with a inhibitary rate of 74.5%.The expression of VEGF mRNA in Ertotinib treated groups (=50?mol/L) were decreased comparing to the control group.The VEGF expression in xeno- grafts tumor tissues was also markedly down-regulated.The MVI) was significantly decreased in Erlotinib treated group( 1.86?0.43)than that in the control group (5.98?1.27,P